Biomarker analysis of WJOG6410L/IMPACT: A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (Stage II-III) non-small cell lung cancer patients with EGFR mutation

Biomarker analysis of WJOG6410L/IMPACT: A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (Stage II-III) non-small cell lung cancer patients with EGFR mutation - WJOG6410LTR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044738

Enrollment

200

Registered

2021-07-02

Start date

2021-04-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Completely resected (Stage II-III) non-small cell lung cancer patients with EGFR mutation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Enrolled in WJOG6410L/IMPACT study 2) Submittable FFPE specimens from surgically resected tumor 3) Consented to participate in this study

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
To clarify the markers which predict the efficacy of EGFR-TKI in completely resected NSCLC patients with EGFR mutation	—

Secondary

Measure	Time frame
To clarify the markers which predict the risk of postoperative recurrence in completely resected NSCLC patients with EGFR mutation	—

Countries

Japan

Contacts

Public ContactSatoshi Ikeda

Kanagawa Cardiovascular and Respiratory Center Department of Respiratory Medicine / Clinical Research Center

isatoshi0112@gmail.com0457019581

Outcome results